Figure 4:
a) Cabozantinib significantly reduced glucose uptake measured by [18F] FDG-PET on day 7 and day 28 of treatment compared to baseline; b) Western Blot analysis revealed a decrease in protein expression of pyruvate dehydrogenase after cabozantinib treatment compared to regorafenib and control.